Compound 42: In-Vivo and In-Vitro Pharmacology Data for a Dual URAT1/GLUT9 Inhibitor

A Novel Pyrrole Acylsulfonamide, Compound 42, as a Dual URAT1/GLUT9 Inhibitor is a dataset from figshare, authored by Zhenqian Wang and last updated on 2026-04 17. The data likely contains experimental results for a novel compound designed for hyperuricemia and gout therapy. It includes in-vivo efficacy metrics, in-vitro IC50 values for key transporters, and pharmacokinetic parameters.

Use Cases

• Compare urate-lowering efficacy between compounds based on the reported decrease ratio of 88.76% in mice.
• Analyze transporter inhibition profiles based on IC50 values for URAT1, GLUT9, and OAT1.
• Evaluate drug candidate pharmacokinetics based on reported half-life (T1/2 = 5.55 h) and bioavailability (F = 51.3%).
• Assess ligand efficiency and druggability based on the reported LE value of 0.44.
• Model potential toxicity reduction based on the comparison of OAT1 off-target activity with lead compound ZS-24.

Strengths

• Includes specific, quantitative efficacy metrics such as a serum urate decrease ratio of 88.76% in acute hyperuricemia mice.
• Provides precise in-vitro assay results, including IC50 values for URAT1 (2.81 ± 0.40 μM) and GLUT9 (12.53 ± 1.33 μM).
• Contains comparative data against a known therapeutic (Lesinurad) and a lead compound (ZS-24) for benchmarking.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is limited to a single compound and specific mouse models, which may narrow generalizability.

Provenance

Source

Zhenqian Wang via figshare

Collection Method

Likely contains experimental data from pharmacological studies in mouse models.

Time Range

null

Freshness

Last updated 2026-04-17 23:29:34; freshness should be verified.

Geography

null